CoroVacc – Development of a SARS-CoV-2 specific vaccine based on attenuated carrier viruses

Due to a modular approach by the Fraunhofer Institutes IGB and IZI, the carrier virus can be developed with SARS-CoV-2 specific antigens at short notice and tested with regard to its vaccination effect.

Vaccine.
Vaccine.

Further spread of COVID-19 can only be stopped and the associated protective measures in the population and the economy eased if a large part of the population is immune to the virus. The greatest hopes here lie in the development of vaccines to prevent a resurgence of the epidemic and to provide lasting protection for people who are not yet infected.

In the the anti-corona project CoroVacc, the Fraunhofer Institutes IGB and IZI aim to develop an attenuated SARS-CoV-2 specific vaccine virus. For this purpose, they combine the competencies in virus engineering (IGB) with vaccine development through to testing in animal models (IZI). Attenuated viruses are highly effective because they induce both the humoral (formation of pathogen-specific antibodies) and the cellular (T-cell-mediated) immune response.

Due to a modular approach, the SARS-CoV-2 specific carrier virus can be developed and tested for its vaccination effect even at short notice. As soon as the first preclinical results are available, the CoroVacc platform virus will be offered to interested companies for further development.

Project information

Project title

CoroVacc – Development of a SARS-CoV-2 specific vaccine based on attenuated carrier viruses

 

Project duration

July 2020 – June 2021

 

Project partners

Fraunhofer IZI

 

Project funding

This work was supported by the Fraunhofer InternaI Programs under Grant No. Anti-Corona 840234 (»Fraunhofer vs. Corona«)